Computational analyses of curcuminoid analogs against kinase domain of HER2

BMC Bioinformatics

Kiattawee Choowongkomon³  Apichart Suksamrarn¹  Sissades Tongsima⁶  Wanwimon Mokmak⁶  Natharinee Horata²  Suwanna Semsri²  Orathai Sawatdichaikul⁴  Wannarat Yim-im⁵ 

[1]Department of Chemistry and Center of Excellence for Innovation in Chemistry, Faculty of Science, Ramkhamhaeng University, Bangkok 10240, Thailand

[2]Faculty of medical technology, Huachiew Chalermprakiet University, Samut, Prakarn 10540, Thailand

[3]Center for Advanced Studies in Tropical Natural Resources, National Research University-Kasetsart University, Kasetsart University, Chatuchak, Bangkok 10900, Thailand

[4]Institute of Food Research and Product Development, Kasetsart University, 50 Ngam Wong Wan Rd, Chatuchak, Bangkok 10900, Thailand

[5]Genetic Engineering Interdisciplinary Program, Graduate School, Kasetsart University, 50 Ngam Wong Wan Rd, Chatuchak, Bangkok 10900, Thailand

[6]National Center for Genetic Engineering and Biotechnology, 113 Thailand Science Park, Phahonyothin Road, Khlong Nueng, Khlong Luang, PathumThani 12120, Thailand

关键词: Molecular dynamics simulation;    Docking;    Curcuminoid analogs;    Tyrosine kinase;    HER2;   

Others  :  1087531
DOI  :  10.1186/1471-2105-15-261

 received in 2014-02-03, accepted in 2014-07-28,  发布年份 2014

【 摘 要 】

Background

Human epidermal growth factor receptor 2 (HER2) has an important role in cancer aggressiveness and poor prognosis. HER2 has been used as a drug target for cancers. In particular, to effectively treat HER2-positive cancer, small molecule inhibitors were developed to target HER2 kinase. Knowing that curcumin has been used as food to inhibit cancer activity, this study evaluated the efficacy of natural curcumins and curcumin analogs as HER2 inhibitors using in vitro and in silico studies. The curcumin analogs considered in this study composed of 4 groups classified by their core structure, β-diketone, monoketone, pyrazole, and isoxazole.

Results

In the present study, both computational and experimental studies were performed. The specificity of curcumin analogs selected from the docked results was examined against human breast cancer cell lines. The screened curcumin compounds were then subjected to molecular dynamics simulation study. By modifying curcumin analogs, we found that protein-ligand affinity increases. The benzene ring with a hydroxyl group could enhance affinity by forming hydrophobic interactions and the hydrogen bond with the hydrophobic pocket. Hydroxyl, carbonyl or methoxy group also formed hydrogen bonds with residues in the adenine pocket and sugar pocket of HER2-TK. These modifications could suggest the new drug design for potentially effective HER2-TK inhibitors. Two outstanding compounds, bisdemethylcurcumin (AS-KTC006) and 3,5-bis((E)-3,4-dimethoxystyryl)isoxazole (AS-KTC021 ),were well oriented in the binding pocket almost in the simulation time, 30 ns. This evidence confirmed the results of cell-based assays and the docking studies. They possessed more distinguished interactions than known HER2-TK inhibitors, considering them as a promising drug in the near future.

Conclusions

The series of curcumin compounds were screened using a computational molecular docking and followed by human breast cancer cell lines assay. Both AS-KTC006 and AS-KTC021 could inhibit breast cancer cell lines though inhibiting of HER2-TK. The intermolecular interactions were confirmed by molecular dynamics simulation studies. This information would explore more understanding of curcuminoid structures and HER2-TK.

【 授权许可】

   
2014 Yim-im et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Holbro T, Civenni G, Hynes NE: The ErbB receptors and their role in cancer progression. Exp Cell Res 2003, 284(1):99-110.
• [2]Pinkas-Kramarski R, Eilam R, Alroy I, Levkowitz G, Lonai P, Yarden Y: Differential expression of NDF/neuregulin receptors ErbB-3 and ErbB-4 and involvement in inhibition of neuronal differentiation. Oncogene 1997, 15(23):2803-2815.
• [3]Pinkas-Kramarski R, Shelly M, Guarino BC, Wang LM, Lyass L, Alroy I, Alimandi M, Kuo A, Moyer JD, Lavi S, Eisenstein M, Ratzkin BJ, Seger R, Bacus SS, Pierce JH, Andrews GC, Yarden Y: ErbB tyrosine kinases and the two neuregulin families constitute a ligand-receptor network. Mol Cell Biol 1998, 18(10):6090-6101.
• [4]Tai W, Mahato R, Cheng K: The role of HER2 in cancer therapy and targeted drug delivery. J Control Release 2010, 146(3):264-275.
• [5]Klapper LN, Kirschbaum MH, Sela M, Yarden Y: Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv Cancer Res 2000, 77:25-79.
• [6]Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, Gómez H, Dinh P, Fauria K, Van Dooren V, Aktan G, Goldhirsch A, Chang TW, Horváth Z, Coccia-Portugal M, Domont J, Tseng L, Kunz G, Sohn JH, Semiglazov V, Lerzo G, Palacova M, Probachai V, Pusztai L, Untch M, Gelber RD, Piccart-Gebhart M: Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. The Lancet 2012, 379(9816):633-640.
• [7]Aertgeerts K, Skene R, Yano J, Sang B-C, Zou H, Snell G, Jennings A, Iwamoto K, Habuka N, Hirokawa A, Ishikawa T, Tanaka T, Miki H, Ohta Y, Sogabe S: Structural analysis of the mechanism of inhibition and allosteric activation of the kinase domain of HER2 protein. J Biol Chem 2011, 286(21):18756-18765.
• [8]Guarneri V, Lenihan DJ, Valero V, Durand JB, Broglio K, Hess KR, Michaud LB, Gonzalez-Angulo AM, Hortobagyi GN, Esteva FJ: Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson cancer center experience. J Clin Oncol 2006, 24(25):4107-4115.
• [9]Scaltriti M, Baselga J: The epidermal growth factor receptor pathway: A model for targeted therapy. Clin Cancer Res 2006, 12(18):5268-5272.
• [10]Slamon D, Clark G, Wong S, Levin W, Ullrich A, McGuire W: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182.
• [11]Ishikawa T, Seto M, Banno H, Kawakita Y, Oorui M, Taniguchi T, Ohta Y, Tamura T, Nakayama A, Miki H, Kamiguchi H, Tanaka T, Habuka N, Sogabe S, Yano J, Aertgeerts K, Kamiyama K: Design and synthesis of novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors bearing a pyrrolo[3,2-d]pyrimidine scaffold. J Med Chem 2011, 54(23):8030-8050.
• [12]Ammon HP, Wahl MA: Pharmacology of Curcuma longa. Planta medica 1991, 57(1):1-7.
• [13]Aggarwal BB, Kumar A, Bharti AC: Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res 2003, 23(1A):363-398.
• [14]Sreejayan , Rao MN: Nitric oxide scavenging by curcuminoids. J Pharm Pharmacol 1997, 49(1):105-107.
• [15]Rao CV, Rivenson A, Simi B, Reddy BS: Chemoprevention of colon carcinogenesis by dietary curcumin, a naturally occurring plant phenolic compound. Cancer Res 1995, 55(2):259-266.
• [16]Kuttan R, Bhanumathy P, Nirmala K, George MC: Potential anticancer activity of turmeric (Curcuma longa). Canc Lett 1985, 29(2):197-202.
• [17]Anuchapreeda S, Thanarattanakorn P, Sittipreechacharn S, Chanarat P, Limtrakul P: Curcumin inhibits WT1 gene expression in human leukemic K562 cells. Acta Pharmacol Sin 2006, 27(3):360-366.
• [18]Dorai T, Gehani N, Katz A: Therapeutic potential of curcumin in human prostate cancer. II. Curcumin inhibits tyrosine kinase activity of epidermal growth factor receptor and depletes the protein. Mol Urol 2000, 4(1):1-6.
• [19]Senft C, Polacin M, Priester M, Seifert V, Kogel D, Weissenberger J: The nontoxic natural compound Curcumin exerts anti-proliferative, anti-migratory, and anti-invasive properties against malignant gliomas. BMC cancer 2010, 10:491.
• [20]Bengmark S: Curcumin, an atoxic antioxidant and natural NFkappaB, cyclooxygenase-2, lipooxygenase, and inducible nitric oxide synthase inhibitor: a shield against acute and chronic diseases. JPEN Journal of parenteral and enteral nutrition 2006, 30(1):45-51.
• [21]Changtam C, de Koning HP, Ibrahim H, Sajid MS, Gould MK, Suksamrarn A: Curcuminoid analogs with potent activity against Trypanosoma and Leishmania species. Eur J Med Chem 2010, 45(3):941-956.
• [22]Changtam C, Hongmanee P, Suksamrarn A: Isoxazole analogs of curcuminoids with highly potent multidrug-resistant antimycobacterial activity. Eur J Med Chem 2010, 45(10):4446-4457.
• [23]Su J, Sripanidkulchai K, Suksamrarn A, Hu Y, Piyachuturawat P, Sripanidkulchai B: Pharmacokinetics and organ distribution of diarylheptanoid phytoestrogens from Curcuma comosa in rats. J Nat Med 2012, 66(3):468-475.
• [24]Suksamrarn A, Ponglikitmongkol M, Wongkrajang K, Chindaduang A, Kittidanairak S, Jankam A, Yingyongnarongkul BE, Kittipanumat N, Chokchaisiri R, Khetkam P, Piyachaturawat P: Diarylheptanoids, new phytoestrogens from the rhizomes of Curcuma comosa: Isolation, chemical modification and estrogenic activity evaluation. Bioorg Med Chem 2008, 16(14):6891-6902.
• [25]Tocharus J, Jamsuwan S, Tocharus C, Changtam C, Suksamrarn A: Curcuminoid analogs inhibit nitric oxide production from LPS-activated microglial cells. J Nat Med 2012, 66(2):400-405.
• [26]Winuthayanon W, Suksen K, Boonchird C, Chuncharunee A, Ponglikitmongkol M, Suksamrarn A, Piyachaturawat P: Estrogenic activity of diarylheptanoids from Curcuma comosa Roxb. requires metabolic activation. J Agric Food Chem 2009, 57(3):840-845.
• [27]Korutla L, Kumar R: Inhibitory effect of curcumin on epidermal growth factor receptor kinase activity in A431 cells. Biochim Biophys Acta 1994, 1224(3):597-600.
• [28]Korutla L, Cheung JY, Mendelsohn J, Kumar R: Inhibition of ligand-induced activation of epidermal growth factor receptor tyrosine phosphorylation by curcumin. Carcinogenesis 1995, 16(8):1741-1745.
• [29]Hong RL, Spohn WH, Hung MC: Curcumin inhibits tyrosine kinase activity of p185neu and also depletes p185neu. Clin Cancer Res 1999, 5(7):1884-1891.
• [30]Tikhomirov O, Carpenter G: Identification of ErbB-2 kinase domain motifs required for geldanamycin-induced degradation. Cancer Res 2003, 63(1):39-43.
• [31]Cowley S, Paterson H, Kemp P, Marshall CJ: Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells. Cell 1994, 77(6):841-852.
• [32]Minden A, Lin A, McMahon M, Lange-Carter C, Derijard B, Davis RJ, Johnson GL, Karin M: Differential activation of ERK and JNK mitogen-activated protein kinases by Raf-1 and MEKK. Science 1994, 266(5191):1719-1723.
• [33]Reddy S, Aggarwal BB: Curcumin is a non-competitive and selective inhibitor of phosphorylase kinase. FEBS letters 1994, 341(1):19-22.
• [34]Liu JY, Lin SJ, Lin JK: Inhibitory effects of curcumin on protein kinase C activity induced by 12-O-tetradecanoyl-phorbol-13-acetate in NIH 3T3 cells. Carcinogenesis 1993, 14(5):857-861.
• [35]Catania A, Barrajon-Catalan E, Nicolosi S, Cicirata F, Micol V: Immunoliposome encapsulation increases cytotoxic activity and selectivity of curcumin and resveratrol against HER2 overexpressing human breast cancer cells. Breast Canc Res Treat 2013, 141(1):55-65.
• [36]Xu YY, Cao Y, Ma H, Li HQ, Ao GZ: Design, synthesis and molecular docking of alpha, beta-unsaturated cyclohexanone analogous of curcumin as potent EGFR inhibitors with antiproliferative activity. Bioorg Med Chem 2013, 21(2):388-394.
• [37]Yang SC, Chang SS, Chen CY: Identifying HER2 inhibitors from natural products database. PLoS ONE 2011, 6(12):e28793.
• [38]Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, Repasky MP, Knoll EH, Shelley M, Perry JK, Shaw DE, Francis P, Shenkin PS: Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 2004, 47(7):1739-1749.
• [39]Halgren TA, Murphy RB, Friesner RA, Beard HS, Frye LL, Pollard WT, Banks JL: Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J Med Chem 2004, 47(7):1750-1759.
• [40]Duan Y, Wu C, Chowdhury S, Lee MC, Xiong G, Zhang W, Yang R, Cieplak P, Luo R, Lee T: A point-charge force field for molecular mechanics simulations of proteins based on condensed-phase quantum mechanical calculations. J Comput Chem 2003, 24(16):1999-2012.
• [41]Cerutti DS, Duke R, Freddolino PL, Fan H, Lybrand TP: A vulnerability in popular molecular dynamics packages concerning Langevin and Andersen dynamics. J Chem Theor Comput 2008, 4(10):1669-1680.
• [42]Ryckaert J-P, Ciccotti G, Berendsen HJC: Numerical integration of the cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes. J Comput Phys 1977, 23(3):327-341.
• [43]Swanson JMJ, Henchman RH, McCammon JA: Revisiting free energy calculations: a theoretical connection to MM/PBSA and direct calculation of the association free energy. Biophys J 2004, 86(1):67-74.
• [44]Wittayanarakul K, Hannongbua S, Feig M: Accurate prediction of protonation state as a prerequisite for reliable MM‒PB (GB) SA binding free energy calculations of HIV‒1 protease inhibitors. J Comput Chem 2007, 29(5):673-685.
• [45]Jani JP, Finn RS, Campbell M, Coleman KG, Connell RD, Currier N, Emerson EO, Floyd E, Harriman S, Kath JC, Morris J, Moyer JD, Pustilnik LR, Rafidi K, Ralston S, Rossi AM, Steyn SJ, Wagner L, Winter SM, Bhattacharya SK: Discovery and pharmacologic characterization of CP-724,714, a selective ErbB2 tyrosine kinase inhibitor. Cancer Res 2007, 67(20):9887-9893.
• [46]Rusnak DW, Affleck K, Cockerill SG, Stubberfield C, Harris R, Page M, Smith KJ, Guntrip SB, Carter MC, Shaw RJ, Jowett A, Stables J, Topley P, Wood ER, Brignola PS, Kadwell SH, Reep BR, Mullin RJ, Alligood KJ, Keith BR, Crosby RM, Murray DM, Knight WB, Gilmer TM, Lackey K: The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer. Cancer Res 2001, 61(19):7196-7203.
• [47]Wood ER, Truesdale AT, McDonald OB, Yuan D, Hassell A, Dickerson SH, Ellis B, Pennisi C, Horne E, Lackey K, Alligood KJ, Rusnak DW, Gilmer TM, Shewchuk L: A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res 2004, 64(18):6652-6659.
• [48]Wissner A, Berger DM, Boschelli DH, Floyd MB Jr, Greenberger LM, Gruber BC, Johnson BD, Mamuya N, Nilakantan R, Reich MF, Bertucci F: 4-Anilino-6,7-dialkoxyquinoline-3-carbonitrile inhibitors of epidermal growth factor receptor kinase and their bioisosteric relationship to the 4-anilino-6,7-dialkoxyquinazoline inhibitors. J Med Chem 2000, 43(17):3244-3256.
• [49]Arkin M, Moasser MM: HER-2-directed, small-molecule antagonists. Curr Opin Investig Drugs 2008, 9(12):1264-1276.
• [50]Charafe-Jauffret E, Ginestier C, Monville F, Finetti P, Adelaide J, Cervera N, Fekairi S, Xerri L, Jacquemier J, Birnbaum D, Bertucci F: Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene 2006, 25(15):2273-2284.
• [51]Lacroix M, Leclercq G: Relevance of breast cancer cell lines as models for breast tumours: an update. Breast Canc Res Treat 2004, 83(3):249-289.
• [52]Lacroix M, Toillon RA, Leclercq G: p53 and breast cancer, an update. Endocr Relat Canc 2006, 13(2):293-325.
• [53]Levenson AS, Jordan VC: MCF-7: the first hormone-responsive breast cancer cell line. Cancer Res 1997, 57(15):3071-3078.
• [54]Ross DT, Perou CM: A comparison of gene expression signatures from breast tumors and breast tissue derived cell lines. Dis Markers 2001, 17(2):99-109.
• [55]Cai X, Zhai H-X, Wang J, Forrester J, Qu H, Yin L, Lai C-J, Bao R, Qian C: Discovery of 7-(4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDC-101) as a Potent Multi-Acting HDAC, EGFR, and HER2 Inhibitor for the Treatment of Cancer. J Med Chem 2010, 53(5):2000-2009.
• [56]Spector N, Xia W, El-Hariry I, Yarden Y, Bacus S: HER2 therapy. Small molecule HER-2 tyrosine kinase inhibitors. Breast Cancer Res 2007, 9(2):1-8.
• [57]Ahmed M, Sadek MM, Abouzid KA, Wang F: In silico design: extended molecular dynamic simulations of a new series of dually acting inhibitors against EGFR and HER2. J Mol Graph Model 2013, 44:220-231.
• [58]Ahmed M, Sadek MM, Serrya RA, Kafafy A-HN, Abouzid KA, Wang F: Assessment of new anti-HER2 ligands using combined docking, QM/MM scoring and MD simulation. J Mol Graph Model 2013, 40:91-98.